Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 32,800 shares of the firm’s stock in a transaction that occurred on Tuesday, February 12th. The stock was sold at an average price of $176.90, for a total transaction of $5,802,320.00. Following the completion of the transaction, the chief executive officer now owns 75,926 shares in the company, valued at approximately $13,431,309.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of EW stock opened at $176.23 on Thursday. Edwards Lifesciences Corp has a 12 month low of $123.00 and a 12 month high of $178.39. The firm has a market cap of $36.20 billion, a PE ratio of 37.50, a price-to-earnings-growth ratio of 2.22 and a beta of 0.92. The company has a current ratio of 2.61, a quick ratio of 1.92 and a debt-to-equity ratio of 0.19.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, January 31st. The medical research company reported $1.17 EPS for the quarter, meeting the Zacks’ consensus estimate of $1.17. Edwards Lifesciences had a net margin of 19.40% and a return on equity of 31.09%. The firm had revenue of $977.70 million for the quarter, compared to analysts’ expectations of $973.72 million. During the same quarter in the previous year, the business posted $0.94 EPS. As a group, analysts expect that Edwards Lifesciences Corp will post 5.22 earnings per share for the current year.

Several research firms recently weighed in on EW. Citigroup lifted their price target on shares of Edwards Lifesciences from $118.00 to $119.00 and gave the company a “sell” rating in a report on Wednesday, January 2nd. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price target for the company from $180.00 to $190.00 in a report on Friday, January 18th. Cowen set a $190.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a report on Monday, December 10th. Deutsche Bank began coverage on shares of Edwards Lifesciences in a report on Wednesday, January 2nd. They issued a “hold” rating and a $164.00 price target on the stock. Finally, Credit Suisse Group began coverage on shares of Edwards Lifesciences in a report on Monday, December 17th. They issued an “outperform” rating and a $188.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $169.86.

Several institutional investors and hedge funds have recently bought and sold shares of the company. RMB Capital Management LLC raised its position in shares of Edwards Lifesciences by 1.5% in the 4th quarter. RMB Capital Management LLC now owns 171,645 shares of the medical research company’s stock worth $26,291,000 after purchasing an additional 2,583 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Edwards Lifesciences by 7.4% in the 4th quarter. Geode Capital Management LLC now owns 2,942,494 shares of the medical research company’s stock worth $449,976,000 after purchasing an additional 202,248 shares during the last quarter. Kinneret Advisory LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth about $799,000. Neuburgh Advisers LLC raised its position in shares of Edwards Lifesciences by 11.6% in the 4th quarter. Neuburgh Advisers LLC now owns 5,918 shares of the medical research company’s stock worth $906,000 after purchasing an additional 616 shares during the last quarter. Finally, California State Teachers Retirement System raised its position in shares of Edwards Lifesciences by 2.6% in the 4th quarter. California State Teachers Retirement System now owns 346,133 shares of the medical research company’s stock worth $53,017,000 after purchasing an additional 8,677 shares during the last quarter. 87.15% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.watchlistnews.com/michael-a-mussallem-sells-32800-shares-of-edwards-lifesciences-corp-ew-stock/2819153.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Further Reading: Stock Split

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.